Director Biology Haematology Science (Myeloid)
Acerta Pharma is a Haematological Oncology R&D centre of expertise of AstraZeneca. We turn ideas into life changing medicines for haematological malignancies. Working here means being entrepreneurial, thinking big and working globally together with AstraZeneca to make the impossible a reality. Our goal is to be at the forefront of developing the next generation of cancer therapies.
As part of the ambitious expansion plans of the research site in Oss, The Netherlands, we have an exciting opportunity for an ambitious and experienced Director, Haematology Science. In this role, you'll play a pivotal role in channeling our scientific capabilities in the discovery and development of novel therapies for the treatment of haematological malignancies.
Director Biology Haematology Science (Myeloid)
As our new Director Haematology Science (Myeloid), you will have a key leadership role in the Biology Group and give strategic direction to the scientific projects, and you will work together and align with your international colleagues from AstraZeneca. Based on your scientific experience and leadership skills you will serve as a mentor and leader to members of the team and at the same time be a strong advisor at senior management level.
You will combine your proven skills of people and matrix leadership, strategy and scientific insight to create a culture that both empowers and support the teams, and enables Acerta Pharma to successfully achieve our company goals. You will work closely together with your ‘peer’ Director Biology Haematology (Lymphoid).
What will you be doing?
• Within the specific scientific area of expertise (e.g. B or T cell lymphoma, chronic lymphocytic leukemia, plasma cell dyscrasia, acute leukemia etc.) :
o Identify new project opportunities to strengthen the AstraZeneca and Acerta Pharma haematologies preclinical and early clinical portfolio.
o Build platform of evidence to strengthen the level of validation supporting a new target to allow full assessment against the generic criteria applied at Target Selection Investment Decision (TSID).
o Identify key individuals and expert medical centers to collaborate with (as part of the broader disease area and biology strategy) to strengthen the quality of the pre-clinical portfolio.
o For new drug targets, develop data packages linking specific molecular targets to patient sub-groups to build patient selection strategies.
• Working with colleague AZ scientists in Haematology, Early Oncology and Biopharm to:
o Contribute to the design of appropriate screening cascades with particular emphasis on the selection of the most relevant disease-based models with initial assessment on potential biomarkers.
o Support discovery projects for compounds which may have additional line of sight to the specific area of haematological expertise.
o Ensure that cross-portfolio platforms (e.g. cell based screening panels, CRISPR capability, PDx access etc.) are appropriate to meet the needs of discovery projects in the specific haematological malignancy.
o Take accountability for the scientific review of external proposals relating to the specific biology area of expertise.
o Support the development of the long term disease area strategy.
• As a key member of the Haematology leadership group in the Netherlands you:
o Communicate research and clinical findings within internal teams and internal governance bodies as appropriate to support decision making.
o Demonstrate excellent managerial skills to enable your global team to deliver on their objectives and to develop their careers.
o Provide input on people development, resources and budget allocations.
o Direct the proper use and implementation for new technology to establish long-term research plans.
What do you bring?
• Advanced degree, PhD and/or MD, with 6+ years’ post-doctoral experience as either an independent academic and/or a pharmaceutical R&D scientist.
• Deep knowledge of, and hands-on strong experience of research in the fundamental biology of one or more haematological malignancies, e.g. B or T cell lymphoma, chronic lymphocytic leukemia, plasma cell dyscrasia, acute leukemia etc.
• Deep knowledge of haematology drug development including development pathways and key trends.
• Strong external network, being recognized by peers as an expert in the field.
• Experience of target selection / validation for novel targets in haematological malignancies and project initiation.
• Strong evidence of leading cross functional (global) teams working in a complex organisation and demonstrated ability to deliver projects to milestones.
• Up to date understanding of the key scientific and clinical areas of focus within the Haematology strategy with proven ability to engage key internal and external partners.
• Critical strategic thinker and highly analytical; ability to initiate, develop and implement new strategies and processes.
• Strong analytical, oral and written communication skills.
• Demonstrated ability to develop more junior scientist and build industry-leading scientific capabilities.
• You have a track record of scientific visibility through publications, patents and presentations at conferences.
What do we offer you?
• A dynamic, innovative and growing international working environment where you will be part of the development of new medicines that can make a difference in patient’s lives. We offer a collaborative, passionate working environment
• The opportunity to work in an ambitious team, with an excellent working atmosphere.
• The opportunity to further develop yourself, international growing possibilities at for example AstraZeneca
• The possibility to work together with your international colleagues in the US, UK from AstraZeneca.
• Great salary and secondary benefits including 8% holiday allowance, 25 holidays on a full-time basis. Collective pension with a fixed percentage personal contribution, bonus scheme.
As part of the significant expansion plans for our R&D site in Oss, the Netherlands, we currently looking for 2 experienced Directors who will drive innovation and have a significant impact on the scientific direction of the bioscience department and in the disease areas we are strategically aligned with. We expect this person to give strategic direction to the preclinical portfolio and to have a critical research function within a rapidly growing international research organisation.
At our international headquarters in Oss, the Netherlands, we are working hard to develop new treatment options for patients with specific types of (blood) cancer. Together with our colleagues of AstraZeneca in San Francisco, Boston and Cambridge (UK)we are committed to innovative drug research and development, especially in the field of haematological oncology. Acerta has received approval from both the US (FDA) and the European Regulator (EMA) for its small molecule BTK inhibitor for treatment of patients with chronic lymphocytic leukaemia (CLL). In addition, AstraZeneca and Acerta Pharma are collaborating on a large number of other innovative medicines with small molecules and biologic drugs to treat certain haematological malignant diseases.
How to apply:
We would like to receive your English CV. In order to apply, go to the apply button at the bottom of this vacancy. You can upload your CV and cover letter at the bottom of the second page.
If you have any questions about this vacancy, our Recruitment team (Karin Raadschelders, Caroline van Oppen, Maaike Willems) can be reached via email@example.com or on +31(0)85 - 047 0244.
AstraZeneca embraces diversity and equality of opportunity. We are committed to building an inclusive and diverse team representing all backgrounds, with as wide a range of perspectives as possible, and harnessing industry-leading skills. We believe that the more inclusive we are, the better our work will be. We welcome and consider applications to join our team from all qualified candidates, regardless of their characteristics. We comply with all applicable laws and regulations on non-discrimination in employment (and recruitment), as well as work authorisation and employment eligibility verification requirements.